Kissei Pharmaceutical Co., Ltd.

Kissei announced Theramex received EC approval for YSELTY® (linzagolix) for endometriosis, in addition to uterine fibroids. The drug is being developed for both conditions in Japan and by out-licensed companies globally. Kissei remains committed to improving patients' QOL worldwide.

Kissei announced Theramex's first commercial sale of YSELTY®, a GnRH receptor antagonist for uterine fibroids, in Germany. The drug, developed by Kissei and licensed to Theramex, received marketing approval in 2022 and offers a new treatment option for patients unable to take hormonal agents. Kissei is committed to improving patient QOL worldwide.